sphingomyelin c17 0 standard Search Results


17:0 pc  (Avanti Polar)
95
Avanti Polar 17:0 pc
17:0 Pc, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/17%3A0+PC/custom%40850360p%4010%2E1016%2Fj%2Eisci%2E2025%2E113248
Average 95 stars, based on 1 article reviews
17:0 pc - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
c17 ceramide  (Avanti Polar)
91
Avanti Polar c17 ceramide
C17 Ceramide, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/C17+Ceramide/custom%40860517p%4019267410
Average 91 stars, based on 1 article reviews
c17 ceramide - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
sphingomyelin  (Avanti Polar)
92
Avanti Polar sphingomyelin
Sphingomyelin, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/Sphingomyelin/pmc03868783-175-14-20
Average 92 stars, based on 1 article reviews
sphingomyelin - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
17:0 sm  (Avanti Polar)
91
Avanti Polar 17:0 sm
17:0 Sm, supplied by Avanti Polar, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/17%3A0+SM/custom%40860585p%4042103229
Average 91 stars, based on 1 article reviews
17:0 sm - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
c18 d3 gm1  (Croda International Plc)
93
Croda International Plc c18 d3 gm1
Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides <t>C18:0</t> to C24:1 are plotted in F), CMH (G), sulfatides (H), and <t>GM1</t> (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.
C18 D3 Gm1, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/C17%3A0+GM1/pm28610891-87-38-40
Average 93 stars, based on 1 article reviews
c18 d3 gm1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
ceramide  (Croda International Plc)
98
Croda International Plc ceramide
Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides <t>C18:0</t> to C24:1 are plotted in F), CMH (G), sulfatides (H), and <t>GM1</t> (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.
Ceramide, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/Ceramide/pm38953353-78-12-21
Average 98 stars, based on 1 article reviews
ceramide - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
c17  (Croda International Plc)
95
Croda International Plc c17
Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides <t>C18:0</t> to C24:1 are plotted in F), CMH (G), sulfatides (H), and <t>GM1</t> (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.
C17, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/sphingosine-d7/pm33755599-314-5-15
Average 95 stars, based on 1 article reviews
c17 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
c16:0-d3 laccer  (Matreya LLC)
90
Matreya LLC c16:0-d3 laccer
Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides <t>C18:0</t> to C24:1 are plotted in F), CMH (G), sulfatides (H), and <t>GM1</t> (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.
C16:0 D3 Laccer, supplied by Matreya LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/gm3+d18+1+18+0+d3/pm28610891-87-21-25
Average 90 stars, based on 1 article reviews
c16:0-d3 laccer - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
c15:0 galcer  (Matreya LLC)
90
Matreya LLC c15:0 galcer
Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides <t>C18:0</t> to C24:1 are plotted in F), CMH (G), sulfatides (H), and <t>GM1</t> (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.
C15:0 Galcer, supplied by Matreya LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/galcer/pm28610891-87-17-20
Average 90 stars, based on 1 article reviews
c15:0 galcer - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
c17:0 gb3cer gb3cer gb4cer  (Matreya LLC)
90
Matreya LLC c17:0 gb3cer gb3cer gb4cer
Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides <t>C18:0</t> to C24:1 are plotted in F), CMH (G), sulfatides (H), and <t>GM1</t> (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.
C17:0 Gb3cer Gb3cer Gb4cer, supplied by Matreya LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/c+12++nbd+gb3cer/pmc05555164-98-27-33
Average 90 stars, based on 1 article reviews
c17:0 gb3cer gb3cer gb4cer - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
c15:0 galcer cmh  (Matreya LLC)
90
Matreya LLC c15:0 galcer cmh
Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides <t>C18:0</t> to C24:1 are plotted in F), CMH (G), sulfatides (H), and <t>GM1</t> (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.
C15:0 Galcer Cmh, supplied by Matreya LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/c15+0+galcer+cmh/pm28610891-87-16-20
Average 90 stars, based on 1 article reviews
c15:0 galcer cmh - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
c16:0-d 3 laccer for cdh  (Matreya LLC)
90
Matreya LLC c16:0-d 3 laccer for cdh
Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides <t>C18:0</t> to C24:1 are plotted in F), CMH (G), sulfatides (H), and <t>GM1</t> (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.
C16:0 D 3 Laccer For Cdh, supplied by Matreya LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sphingomyelin+c17+0+standard/n+hexadecanoyl++d+++erythro++sphingosine+1+phosphate++c16+0+ceramide+1+phosphate+++c1p+/pmc05555164-98-21-26
Average 90 stars, based on 1 article reviews
c16:0-d 3 laccer for cdh - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides C18:0 to C24:1 are plotted in F), CMH (G), sulfatides (H), and GM1 (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.

Journal: Neurobiology of disease

Article Title: N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV.

doi: 10.1016/j.nbd.2017.06.003

Figure Lengend Snippet: Fig. 4. Cerebellar lipid analysis via mass spectrometry reveals alterations in the Mcoln1−/−lipid profile with improvements to specific lipid classes upon miglustat treatment. A) Schematic of GSL synthesis pathway and abbreviations used. Purported point of action of miglustat denoted in red. B–D) Total levels detected for each lipid listed in cerebellum, including those enriched in white matter (B), complex gangliosides (C), and ceramide & globo-series glycolipids (D). E–I) Major (ie, most prevalent) isoforms detected are plotted for each lipid (complete isoform analysis plotted in Supp. Fig. 3–5.), including ceramides (E, ratio of ceramides C18:0 to C24:1 are plotted in F), CMH (G), sulfatides (H), and GM1 (I). n = 4 per group. Differences were detected by two-way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, C24:1 CMH, and C24:1 sulfatide; for treatment in the ratio of C18:0/C24:1 ceramide; and for both genotype and treatment in total GM1 and C18:0 GM1. Where appropriate, post hoc pairwise comparisons were made with significant differences detected between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.

Article Snippet: To quantitate, the following internal standards were added to the samples: C17:0 ceramide (Avanti Polar Lipids), C15:0 GalCer for CMH (Matreya), C16:0-D3 LacCer for CDH (Matreya), C17:0 Gb3Cer for Gb3Cer and Gb4Cer (Matreya), C17:0 sphingomyelin (Avanti Polar Lipids), C18-D3 GM1 (Avanti Polar Lipids), C18-D3 GM2 C18-D3 GM3 (Avanti Polar Lipids) and C12:0 sulfatide (Avanti Polar Lipids).

Techniques: Mass Spectrometry, Saline

Fig. 5. Cerebral lipid analysis in Mcoln1−/−mice reveals changes to the Mcoln1−/−lipid profile not corrected with miglustat. A–C) Total levels of lipids enriched in cerebral white matter, complex gangliosides, and ceramide & globo-series glycolipids are plotted as in Fig. 4. D–H) Major isoforms detected are plotted for each lipid as in Fig. 4 (complete isoform analysis plotted in Supp. Figs. 3–5), including ceramides (D, ratio of ceramides C18:0 to C24:1 are plotted in E), CMH (F), sulfatides (G), and GM1 (H). n = 4 per group. Differences were detected by two- way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, total GM3, C18:0 Cer, C24:1 Cer, C24:1 CMH, and C24:1 sulfatide; for treatment in total GM1, total Gb3Cer, total Gb4Cer, the ratio of C18:0/C24:1 ceramide, and C18:0 GM1. Pairwise comparisons were made when appropriate, with significant differences between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.

Journal: Neurobiology of disease

Article Title: N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV.

doi: 10.1016/j.nbd.2017.06.003

Figure Lengend Snippet: Fig. 5. Cerebral lipid analysis in Mcoln1−/−mice reveals changes to the Mcoln1−/−lipid profile not corrected with miglustat. A–C) Total levels of lipids enriched in cerebral white matter, complex gangliosides, and ceramide & globo-series glycolipids are plotted as in Fig. 4. D–H) Major isoforms detected are plotted for each lipid as in Fig. 4 (complete isoform analysis plotted in Supp. Figs. 3–5), including ceramides (D, ratio of ceramides C18:0 to C24:1 are plotted in E), CMH (F), sulfatides (G), and GM1 (H). n = 4 per group. Differences were detected by two- way ANOVA for genotype in total CMH, total CDH, total sulfatides, total GM2, total GM3, C18:0 Cer, C24:1 Cer, C24:1 CMH, and C24:1 sulfatide; for treatment in total GM1, total Gb3Cer, total Gb4Cer, the ratio of C18:0/C24:1 ceramide, and C18:0 GM1. Pairwise comparisons were made when appropriate, with significant differences between WT saline - Mcoln1−/−saline, Mcoln1−/−saline - Mcoln1−/−miglustat, WT saline - Mcoln1−/−miglustat, and WT saline - WT miglustat denoted. *p b 0.05, **p b 0.01, ***p b 0.001, ****p b 0.0001.

Article Snippet: To quantitate, the following internal standards were added to the samples: C17:0 ceramide (Avanti Polar Lipids), C15:0 GalCer for CMH (Matreya), C16:0-D3 LacCer for CDH (Matreya), C17:0 Gb3Cer for Gb3Cer and Gb4Cer (Matreya), C17:0 sphingomyelin (Avanti Polar Lipids), C18-D3 GM1 (Avanti Polar Lipids), C18-D3 GM2 C18-D3 GM3 (Avanti Polar Lipids) and C12:0 sulfatide (Avanti Polar Lipids).

Techniques: Saline